Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01636388 · ClinicalTrials.gov registry record · Phase 2
Allogeneic Stem Cell Transplantation With Adoptive Immunotherapy in Epstein-Barr Virus Positive Recurrent/Refractory Hodgkins Lymphoma
A Phase 2 study, sponsored by New York Medical College.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT01636388 is a Phase 2 study that was terminated before completion, run by New York Medical College. The registered enrollment target is 2 participants.
The verdict
NCT01636388, a Phase 2 study, was terminated before completion, sponsored by New York Medical College.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
The investigators intend to utilize reduced intensity conditioning and allogeneic stem cell transplant from EBV positive HLA matched sibling or unrelated adult donor combined with post AlloSCT allogeneic donor derived LMP specific cytotoxic T-lymphocyte (CTL) infusions in EBV positive patients with poor risk Hodgkin Lymphoma. One of three reduced intensity conditioning regimens predetermined at each institutional center of the Childhood, Adolescent and Young Adult Lymphoma Cell Therapy Consortium (LCTC) will be utilized for related or matched unrelated adult donor allogeneic transplant followed by donor LMP specific CTL infusion for three doses post AlloSCT. The investigators hypothesize that the addition of donor derived LMP specific CTLs will be safe and feasible.
Interventions
- BIOLOGICAL allogeneic donor derived LMP specific cytotoxic T-lymphocyte
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2013-01 |
| Est. Completion | 2017-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01636388
The ClinicalTrials.gov registry entry for NCT01636388 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New York Medical College, which has 47 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which allogeneic donor derived LMP specific cytotoxic T-lymphocyte is the first listed.
NCT01636388 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01636388 about?
NCT01636388 is a clinical study titled "Allogeneic Stem Cell Transplantation With Adoptive Immunotherapy in Epstein-Barr Virus Positive Recurrent/Refractory Hodgkins Lymphoma". The investigators intend to utilize reduced intensity conditioning and allogeneic stem cell transplant from EBV positive HLA matched sibling or unrelated adult donor combined with post AlloSCT allogeneic donor derived LMP specific cytotoxic T-lymphocyte (CTL) infusions in EBV positive patients with ...
What is the current status of trial NCT01636388?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2013-01. Estimated completion is 2017-12.
What interventions are being tested in trial NCT01636388?
The interventions under investigation include: allogeneic donor derived LMP specific cytotoxic T-lymphocyte (BIOLOGICAL).
Who is sponsoring clinical trial NCT01636388?
This trial is sponsored by New York Medical College, which has 47 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.